UCB Bullish On Bimzelx Despite Sluggish Start

Gaining Market Share In IL-17 Segment

While sales for the dual interleukin-17A and IL-17F inhibitor only reached €35m last year, UCB immunology chief Emmanuel Caeymaex is confident that figure will leap over the €200m barrier in 2023, if US approval for Bimzelx for psoriasis comes in the next quarter. 

UCB
• Source: UCB

As it waits patiently for US approval for Bimzelx in psoriasis, UCB S.A. has given an insight into the European launch of the potential autoimmune disease blockbuster which has started fairly slowly.

More from Earnings

More from Business